Maryland is currently home to 2684 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: University of Maryland Children's Hospital, Baltimore, Maryland
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
Zenith® Fenestrated+ Clinical Study
NCT04875429
Recruiting
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Register for Updates
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: American Oncology Partners, P.A., Bethesda, Maryland
Conditions: Breast Cancer
Register for Updates
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
NCT05665361
Recruiting
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Objective: To test a pair of drugs (sasanlimab and palbociclib) in people with kidney cancers. Eligibility: People aged 18 years and older with kidney cancer; specifically, clear cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC). Design: Participants will be screened. They will... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)
Register for Updates
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
NCT05470504
Recruiting
Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems. Objective: To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance. Eligibility: Adults aged 18 to 65 years with eithe... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Insulin Receptor Mutation, Partial Lipodystrophy
Register for Updates
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
NCT05436418
Recruiting
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Sometimes these transplants cause serious side effects, including a common immunologic problem called graft-versus-host disease. A drug called cyclophosphamide given early after the transplant (post-transplantation cyclophosphamide, PTCy) can reduce these complications. But sometimes this drug has its ow... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Register for Updates
PT-112 in Subjects With Thymoma and Thymic Carcinoma
NCT05104736
Recruiting
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells. It also helps the body s immune system fight cancer. Objective: To see if the study drug PT-112 can cause tumors to shrink. Eligibility: People ages 18 and older who have thymoma or thymic cancer and whose disease returned or progressed after treatment with at least one... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Register for Updates
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
NCT04927416
Recruiting
Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can better detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to a tumor and make it visible during a positron emission tomography/computed tomography (PET/CT) scan. This information might help guide future research and treat... Read More
Gender:
ALL
Ages:
Between 18 years and 98 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastic Thyroid Cancer
Register for Updates
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
NCT04781309
Recruiting
Background: Progressive multifocal leukoencephalopathy (PML) is a brain infection. It is caused by a virus. PML can happen in people with a weakened immune system. PML is associated with cognitive and visual impairment as well as motor and speech disturbances. There is no treatment for PML. Researchers want to see if a new drug can help. Objective: To see if the drug NT-I7 can help increase lymphocyte numbers, which may help control PML infection. Eligibility: Adults ages 18 and older with... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Progressive Multifocal Leukoencephalopathy
Register for Updates
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
NCT04781322
Recruiting
Background: Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning/swelling. Objective: To study the effects of alirocumab in people who drink alcohol. Eligibility: Healthy adults ages 21 to 65 who regularly consume an average of 20 or more drinks per week. Design: Participants will be screened under protocol 14-AA-0181... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Associated Liver Disease, Heavy Drinking Behavior
Register for Updates
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
NCT04417660
Recruiting
Background: Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases, the disease returns after treatment. Researchers want to see if a new drug can help. Objective: To see if bintrafusp alfa (M7824) is an effective treatment for thymoma and thymic carcinoma. Eligibility: People age 18 and older who have thymoma or thymic cancer and their disease returned or progressed after treatment with at least o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Register for Updates
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
NCT04339777
Recruiting
Background: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective: To see if stem cell transplant can be successfully performed in people with primary immunodeficiency disease and cure them. Eligibility: People ages 4-69 for whom a primary immunodeficiency (PID) or Primary Immune Re... Read More
Gender:
ALL
Ages:
Between 4 years and 69 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
Register for Updates